Boston, June 25

Welcome to hubXchange’s Cell Therapy Manufacturing Xchange Boston 2024, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in cell therapy manufacturing.

Discussion topics will cover iPSCs Technology, Autologous, Allogeneic, Measuring Product Potency. 

Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.

Venue: Woburn Hilton Hotel, 2 Forbes Road, Woburn, MA, 01801, US


  • Assessing genetic stability with arrayComparative Genomic Hybridization (aCGH).
  • Addressing heterogeneity challenges using single-cell clonal expansion.
  • Block-chain enabled digital platforms to break down siloes in autologous cell therapy manufacturing.
  • Improving efficiency and reducing inter-batch variation with automated Cell Expansion Systems.
  • Enabling long-term storage and transportation using Cryopreservation Techniques.
  • Implementing microfluidic chip-based assays to provide real-time information on critical quality attributes.
  • Implementing principles of analytical quality by design to address the variations in potency measurement
  • Conducting release and characterization assays for cell therapy

Full Xchange Agenda

Click on each track for detailed agenda

iPSCs Technology

Titles and Bullets
08:00 – 08:30
08:30 – 09:00

Opening Address & Keynote Presentation by Monomer Bio

09:05 – 10:05

Addressing heterogeneity challenges using single-cell clonal expansion

  • Single cell cloning using droplet technology 
  • Rapid expansion of single iPSC using ECM coated 96 well plates
  • Media and growth factors required for clonal expansion

Zhinan Xia has more 25 years of Biopharma industrial experience and many years of CGT experience at Moderna, Dynamicure and Abimmune

Zhinan Xia
10:10 – 10:40
1-2-1 Meetings/Networking Break
10:45 – 11:15
1-2-1 Meetings / Networking Break
11:15 – 11:25
Morning Refreshments
11:25 – 12:25

Sponsor-led Roundtable

12:25 – 13:25

Networking Lunch

13:25 – 13:55

Spotlight Presentation

14:00 – 14:30
1-2-1 Meetings / Networking Break
14:35 – 15:05

1-2-1 Meetings / Networking Break

15:45 – 16:45

Developing iPSC Cells as Therapeutics

  • Clinical grade iPSC line generation: which method is the ideal one ?
  • As fully differentiated cells are the final products, what is the best approach to efficiently eliminate undifferentiated iPSC cells and to avoid tumorigenic potential?
  • CMC and Scale: is industrial scale-up necessary for iPSC-derived cell products? If Yes, what is the best approach ?

Shi-Jiang (John) Lu, PhD, MPH, is currently the President and CEO of HebeCell Corporation, focusing on the development and clinical translation of regenerative medicine and cell therapy technologies, especially iPS-CAR-NK cells for the treatment of cancer, autoimmune and viral infectious diseases. Before establishing HebeCell, he was the Senior Director of Research at Advanced Cell Technology/Ocata Therapeutics, which was acquired by Astellas Pharma in 2016. John is an expert in stem cell biology and regenerative medicine with 20 years of experiences. He has been conducting translational research and discovery of novel therapeutic strategies utilizing human pluripotent stem cells (PSC) and their derivatives. The goal of his research is to generate human PSC-derived products for the treatment of human diseases. He also has extensive experience in process development and large-scale production of human PSC derivatives under defined conditions for clinical trials. John is the inventor of more than 20 patents in stem cell field: in an analysis of global stem cell patent landscape by Nature Biotechnology in 2014, John’s patent application and citation ranked No. 7 and No. 5, respectively. In addition to stem cell research, Dr. Lu also has more than 10 years of experiences in cancer research.

John Lu
16:45 – 17:45

Evening Drinks Reception


Cell Therapy Manufacturing Xchange | Boston 2024